CN114478782B - 抗凝血因子xi抗体 - Google Patents
抗凝血因子xi抗体 Download PDFInfo
- Publication number
- CN114478782B CN114478782B CN202111467365.1A CN202111467365A CN114478782B CN 114478782 B CN114478782 B CN 114478782B CN 202111467365 A CN202111467365 A CN 202111467365A CN 114478782 B CN114478782 B CN 114478782B
- Authority
- CN
- China
- Prior art keywords
- antibody
- fxi
- antibodies
- thrombosis
- fxia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010074864 Factor XI Proteins 0.000 title abstract description 13
- 239000003130 blood coagulation factor inhibitor Substances 0.000 title description 2
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 230000035602 clotting Effects 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 101001062768 Homo sapiens Coagulation factor XI Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 11
- 230000002439 hemostatic effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 2
- 108010080805 Factor XIa Proteins 0.000 abstract description 88
- 239000012634 fragment Substances 0.000 abstract description 20
- 230000015271 coagulation Effects 0.000 abstract description 12
- 238000005345 coagulation Methods 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 description 58
- 208000034158 bleeding Diseases 0.000 description 56
- 230000000740 bleeding effect Effects 0.000 description 56
- 210000002381 plasma Anatomy 0.000 description 53
- 230000000694 effects Effects 0.000 description 45
- 241000282693 Cercopithecidae Species 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 19
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 19
- 230000037361 pathway Effects 0.000 description 18
- 230000002785 anti-thrombosis Effects 0.000 description 17
- 239000003146 anticoagulant agent Substances 0.000 description 17
- 230000017531 blood circulation Effects 0.000 description 17
- 241000282567 Macaca fascicularis Species 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 15
- 206010053567 Coagulopathies Diseases 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 229940127219 anticoagulant drug Drugs 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 8
- 206010014522 Embolism venous Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010059054 Shunt thrombosis Diseases 0.000 description 8
- 206010047249 Venous thrombosis Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 208000004043 venous thromboembolism Diseases 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108090000113 Plasma Kallikrein Proteins 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000001105 femoral artery Anatomy 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 108010094028 Prothrombin Proteins 0.000 description 5
- 102100027378 Prothrombin Human genes 0.000 description 5
- 208000010378 Pulmonary Embolism Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 229940039716 prothrombin Drugs 0.000 description 5
- 230000001732 thrombotic effect Effects 0.000 description 5
- 108050008958 Apple domains Proteins 0.000 description 4
- 102000000443 Apple domains Human genes 0.000 description 4
- 206010003178 Arterial thrombosis Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000002429 anti-coagulating effect Effects 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000006623 intrinsic pathway Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000014508 negative regulation of coagulation Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010071241 Factor XIIa Proteins 0.000 description 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 208000031933 Rare hemorrhagic disease Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006624 extrinsic pathway Effects 0.000 description 2
- 201000007219 factor XI deficiency Diseases 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 208000021331 vascular occlusion disease Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WPVINHLVHHPBMK-ULQDDVLXSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[(2s)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCN1C(=O)[C@@H]1CCC(=O)N1 WPVINHLVHHPBMK-ULQDDVLXSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010005133 Bleeding tendencies Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102100030563 Coagulation factor XI Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- -1 FXI Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 206010072564 Peripheral artery thrombosis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009635 nitrosylation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111467365.1A CN114478782B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/099638 WO2020029179A1 (en) | 2018-08-09 | 2018-08-09 | Anti-factor xi antibodies |
| CN201880098606.XA CN113227150B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
| CN202111467365.1A CN114478782B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880098606.XA Division CN113227150B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114478782A CN114478782A (zh) | 2022-05-13 |
| CN114478782B true CN114478782B (zh) | 2024-04-02 |
Family
ID=69413757
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310301532.8A Withdrawn CN116554334A (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
| CN201880098606.XA Active CN113227150B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
| CN202111466510.4A Active CN114478781B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
| CN202111467365.1A Active CN114478782B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310301532.8A Withdrawn CN116554334A (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
| CN201880098606.XA Active CN113227150B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
| CN202111466510.4A Active CN114478781B (zh) | 2018-08-09 | 2018-08-09 | 抗凝血因子xi抗体 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3833692A1 (ko) |
| JP (1) | JP2021534098A (ko) |
| KR (1) | KR20210042352A (ko) |
| CN (4) | CN116554334A (ko) |
| AU (1) | AU2018436195A1 (ko) |
| BR (1) | BR112021002472A2 (ko) |
| CA (1) | CA3108708A1 (ko) |
| MX (1) | MX2021001613A (ko) |
| WO (1) | WO2020029179A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| CN116554334A (zh) * | 2018-08-09 | 2023-08-08 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| CN113474373A (zh) * | 2019-01-21 | 2021-10-01 | 阿罗诺拉股份有限公司 | 具有抗血栓形成和抗炎作用的新型抗因子xi人源化抗体及其用途 |
| CN115917812A (zh) | 2021-03-31 | 2023-04-04 | 株式会社Lg新能源 | 具有光泽度计的单一单元制造设备和使用该设备的制造方法 |
| CN116410258A (zh) * | 2023-04-13 | 2023-07-11 | 上海太阳生物技术有限公司 | 因子xi缺乏血浆保护剂及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009067660A2 (en) * | 2007-11-21 | 2009-05-28 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| CN104684932A (zh) * | 2012-05-10 | 2015-06-03 | 拜耳药业股份公司 | 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
| CN107922505A (zh) * | 2015-06-26 | 2018-04-17 | 诺华股份有限公司 | 凝血因子xi抗体及使用方法 |
| CN108409863A (zh) * | 2017-02-10 | 2018-08-17 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| CN114478781A (zh) * | 2018-08-09 | 2022-05-13 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014202009A1 (en) * | 2007-11-21 | 2014-05-01 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| TR201820051T4 (tr) * | 2008-06-19 | 2019-01-21 | Prothix Bv | Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması |
| DK2373691T3 (en) * | 2008-12-18 | 2019-04-15 | Oregon Health&Science Univ | ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE |
| JOP20170013B1 (ar) * | 2016-01-22 | 2021-08-17 | Merck Sharp & Dohme | أجسام xi مضادة لعامل مضاد للتجلط |
| KR102448456B1 (ko) * | 2016-03-23 | 2022-09-28 | 프로틱스 비브이 | 인자 xi의 활성 부위에 대한 모노클로날 항체 및 이의 용도 |
-
2018
- 2018-08-09 CN CN202310301532.8A patent/CN116554334A/zh not_active Withdrawn
- 2018-08-09 CN CN201880098606.XA patent/CN113227150B/zh active Active
- 2018-08-09 EP EP18929685.8A patent/EP3833692A1/en not_active Withdrawn
- 2018-08-09 CN CN202111466510.4A patent/CN114478781B/zh active Active
- 2018-08-09 JP JP2021506623A patent/JP2021534098A/ja active Pending
- 2018-08-09 KR KR1020217006922A patent/KR20210042352A/ko unknown
- 2018-08-09 CA CA3108708A patent/CA3108708A1/en not_active Abandoned
- 2018-08-09 WO PCT/CN2018/099638 patent/WO2020029179A1/en unknown
- 2018-08-09 AU AU2018436195A patent/AU2018436195A1/en not_active Abandoned
- 2018-08-09 CN CN202111467365.1A patent/CN114478782B/zh active Active
- 2018-08-09 BR BR112021002472-7A patent/BR112021002472A2/pt not_active Application Discontinuation
- 2018-08-09 MX MX2021001613A patent/MX2021001613A/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009067660A2 (en) * | 2007-11-21 | 2009-05-28 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| CN104684932A (zh) * | 2012-05-10 | 2015-06-03 | 拜耳药业股份公司 | 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
| CN107922505A (zh) * | 2015-06-26 | 2018-04-17 | 诺华股份有限公司 | 凝血因子xi抗体及使用方法 |
| CN108409863A (zh) * | 2017-02-10 | 2018-08-17 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| CN114478781A (zh) * | 2018-08-09 | 2022-05-13 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
Non-Patent Citations (2)
| Title |
|---|
| Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial;Christina U. Lorentz 等;《Arteriosclerosis，Thrombosis， and Vascular Biology》;第39卷(第4期);第 799-809 页 * |
| 人血浆凝血因 子Xi 单克隆抗体的制备 及其应用初探;侯玉香等;《第十一届全国血栓与止血 血栓会议》;第 102-103 页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3833692A1 (en) | 2021-06-16 |
| MX2021001613A (es) | 2021-04-28 |
| CN114478781B (zh) | 2024-04-02 |
| CN113227150A (zh) | 2021-08-06 |
| CN116554334A (zh) | 2023-08-08 |
| AU2018436195A1 (en) | 2021-02-18 |
| CN114478782A (zh) | 2022-05-13 |
| CN114478781A (zh) | 2022-05-13 |
| BR112021002472A2 (pt) | 2021-07-27 |
| WO2020029179A1 (en) | 2020-02-13 |
| CN113227150B (zh) | 2023-07-28 |
| KR20210042352A (ko) | 2021-04-19 |
| CA3108708A1 (en) | 2020-02-13 |
| JP2021534098A (ja) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114478782B (zh) | 抗凝血因子xi抗体 | |
| CN108409863B (zh) | 抗凝血因子xi抗体 | |
| JP7366988B2 (ja) | 抗凝固因子ｘｉ抗体 | |
| JP7303761B2 (ja) | 組織因子経路インヒビター抗体およびその使用 | |
| KR102218714B1 (ko) | 항응고 인자 xi 항체 | |
| EP3558370A2 (en) | Methods of treatment with anti-factor xi/xia antibodies | |
| CN109219447B (zh) | 针对mac-1的抗体 | |
| US11958911B2 (en) | Anti-coagulation factor XI antibody | |
| JP2023532251A (ja) | 抗ＦＸＩ／ＦＸＩａ抗体、その抗原結合断片と医薬用途 | |
| RU2800719C2 (ru) | Антитела к фактору xi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40075244 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |